Please assess the completion status of the following clinical trial:

Trial Title: Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with established, pathologically confirmed diagnoses of newly diagnosed, poor-risk Acute Myeloid Leukemia(AML) including de novo and secondary Acute Myeloid Leukemias but excluding newly diagnosed acute progranulocytic leukemia (APL, M3) will be considered eligible for study~* ECOG performance status 0-2~* Patient must be able to give informed consent~* Serum creatinine =\< 2.0~* ALT, AST =\< 5 x upper limit of normal~* Bilirubin =\< 2.0 mg/dl~* Left ventricular ejection fraction \>= 45%~* Newly diagnosed AML, subtypes M0,1,2,4-7 but excluding M3 (APL) with poor-risk features, including:~  * Age \> 50 years, or age \> 18 years with one or more of the following criteria:~    * Antecedent hematologic disorder including myelodysplasia (MDS)-related AML (MDS/AML) and prior myeloproliferative disorder (MPD)~   * Treatment-related AML~   * AML with trilineage dysplasia (AML-TLD)~   * Adverse cytogenetics (defined as -5/-5q; -7/-7q; abnormal 3q, 9q, 11q, 20q, 21q or 17p; t(6;9); t(9;22); trisomy 8; trisomy 13, complex karyotypes (\>= 3 unrelated abnormalities)~Exclusion Criteria:~* Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for MDS or MPD (e.g., thalidomide or lenalidomide, interferon, cytokines, low-dose 5-azacytidine, low-dose cytoxan) will be eligible for this trial~* Any previous treatment with flavopiridol~* Concomitant chemotherapy, radiation therapy, or immunotherapy~* Hyperleukocytosis with \>= 50,000 blasts/uL; leukapheresis or hydroxyurea may be used immediately prior to study drug administration for cytoreduction; must be stopped 24 hours before first dose of Flavopiridol~* Acute Progranulocytic Leukemia (APL, M3)~* Active CNS leukemia~* Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible~* Presence of other life-threatening illness~* Patients with mental deficits and/or psychiatric history that preclude them form giving informed consent or from following protocol~* Pregnant and nursing patients are excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (alvocidib, cytarabine, mitoxantrone hydrochloride) (Type: EXPERIMENTAL): Patients receive alvocidib IV over 1 hour on days 1-3, cytarabine IV continuously over 72 hours on days 6-8, and mitoxantrone hydrochloride IV over 1-2 hours on day 9. Beginning 35-63 days after completion of course 1, patients achieving complete or partial remission may receive a second course of treatment as above.~Patients age 50 and over with core binding factor acute myeloid leukemia (AML) (e.g., t\[8;21\], inv\[16\], or t\[16;16\]) achieving a complete remission after course 1 of treatment may receive 3-4 courses of consolidation therapy comprising high-dose cytarabine at the discretion of the investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).